Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Closer Look: Dr. Reddy’s Sees Global Leadership In Biosimilars Via Merck Serono Deal

This article was originally published in PharmAsia News

Executive Summary

Dr. Reddy’s CEO spoke with PharmAsia News to discuss the carefully crafted deal.

You may also be interested in...



With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim

MUMBAI - Keeping with its track record of launching a range of biosimilars before its peers, India's Dr. Reddy's Laboratories Ltd. is set to launch its indigenously developed pegylated filgrastim - a version of Amgen Inc.'s blockbuster Neulasta used to boost white blood cells in patients undergoing chemotherapy. Neulasta had global sales of around $3.6 billion last year, said an expert in the biotechnology industry

India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets

Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO; Limited Growth In Generics Will Lead To Moves For Innovative Drugs

MUMBAI - With six biosimilar compounds in the works and two launched in the Indian market, India's second largest generic drug maker - Dr. Reddy's Labs - is negotiating with several multinational companies to broaden its presence in Western markets

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC081326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel